Business
DarioHealth Announces Poster Presentation at the Virtual Association of Diabetes Care and Education Specialists 2020 Annual Conference
Observational study results demonstrate improved blood pressure and glycemic control for patients suffering from hypertensive blood pressure and diabetes who
About this update from Dariohealth Corp.
[{"type":"text","content":"Observational study results demonstrate improved blood pressure and glycemic control for patients suffering from hypertensive blood pressure and diabetes who used the Dario platform\n\n\nNEW YORK, Aug. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that an emerging science industry poster has been accepted for presentation at the virtual Association of Diabetes Care and Education Specialists (ADCES) 2020 Annual Conference, which is being held today, August 13, through August 16, 2020. \n\n \n \n \n \n \n \n\n \nThe poster, entitled, \"Impact of Digital Management on Clinical Outcome in Patients with Chronic Conditions: Diabetes and Hypertension,\" details results from an observational study of 345 participants with hypertensive blood pressure at baseline who utilized the Dario digital therapeutics platform. \nResults:\nBlood pressure\nAll study subjects started with hypertension stage 1, stage 2 or hypertensive crisis levels. They were monitored using the Dario blood pressure monitoring system for three months. 70% of users (243/345) improved their blood pressure reading by 8.4 mmHg Systolic and 6.2 mmHg Diastolic on average (Systolic 134.2 ± 12 versus 142.6 ±14; Diastolic 83.7 ± 8.7 versus 89.9 ± 11). Diabetes\nThe same group of 345 users measured their glucose levels with the Dario digital therapeutics platform for a period of six months or longer. 89% of study participants reported a confirmed diagnosis of prediabetes or Type 2 diabetes. A reduction of 33% (5.4% versus 8.0%) in high readings (>250 mg/dL) and 67% (0.3% versus 0.9%) in severe events (>400 mg/dL) was observed at six months as compared to baseline. A subset of 114 study subjects with elevated baseline blood glucose (>160 mg/dL) improved their average blood glucose by 14% (177 ±50 versus 207 ± 47 mg/dL) as compared to baseline.Notably, the average age of participants in this study was 60.4 years, suggesting that the required use of technology by older individuals does not appear to be a significant barrier to engagement.\nThe paper concludes, \"This observational study of a digital therapeutic platform for chronic disease demonstrates improved blood pressure at three months and glycemic control at six months compared to baseline. These findings suggest that digital therapeutics may he...